Publications
Publications
Show Results For
- All HBS Web
(1,072)
- Faculty Publications (627)
- April 2021 (Revised December 2021)
- Case
The Carlyle Group: Carving Out Atotech
On January 31, 2017, The Carlyle Group ("Carlyle") closed its $3.2 billion acquisition of Atotech, an international Specialty Chemicals and Equipment company. In Carlyle's Washington, DC headquarters, the US-based deal team—Martin Sumner, Greg Nikodem, Tanaka Maswoswe... View Details
- February 2021 (Revised June 2021)
- Case
Barbarians at the Gate or Turnaround Gurus? Private Equity and the Rise of the LBO
By: Tom Nicholas and John Masko
During the 1980s, leveraged buyouts (LBOs) and the private equity (PE) firms responsible for carrying them out revolutionized both investment and management in the U.S. Between 1980 and 1989, buyout activity in the U.S. surged from $1 billion per year to $60 billion.... View Details
Keywords: Leveraged Buyouts; Mergers and Acquisitions; Business Conglomerates; Restructuring; Borrowing and Debt; Private Equity; Bonds; Investment Return; Institutional Investing; Profit Sharing; Business History; Management Style; Private Ownership; Performance Effectiveness; Value Creation; Financial Services Industry; United States
- January 2021
- Case
Takeda Pharmaceutical Company Limited (A)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn... View Details
- January 2021
- Supplement
Takeda Pharmaceutical Company Limited (B)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and... View Details
- January 2021 (Revised June 2021)
- Supplement
Eaton Corporation: Portfolio Transformation and The Cost of Capital (Abridged)
By: Benjamin C. Esty, E. Scott Mayfield and Daniel Fisher
In 2000, Eaton Corporation was a broadly diversified industrial conglomerate. But its strategy was evolving and its focus was narrowing around “power management” and more recently on “intelligent power,” the use of digitally enabled products and services designed to... View Details
- January 2021 (Revised June 2021)
- Case
Eaton Corporation: Portfolio Transformation and the Cost of Capital (Abridged)
By: Benjamin C. Esty, E. Scott Mayfield and Daniel Fisher
In 2000, Eaton Corporation was a broadly diversified industrial conglomerate. But its strategy was evolving and its focus was narrowing around “power management” and more recently on “intelligent power,” the use of digitally enabled products and services designed to... View Details
- 2020
- Working Paper
Dog Eat Dog: Balancing Network Effects and Differentiation in a Digital Platform Merger
By: Chiara Farronato, Jessica Fong and Andrey Fradkin
Digital platforms are increasingly the subject of regulatory scrutiny. In comparison to multiple competitors, a single platform may increase consumer welfare if network effects are large or may decrease welfare due to higher prices or reduction in platform variety. We... View Details
- November 2020 (Revised February 2022)
- Case
CommonSpirit Health: Integrating a Merger of Equals
By: Robert S. Huckman, Hise Gibson and Nicole Gilmore
Soon after closing the 2019 merger of Catholic Health Initiatives (CHI) and Dignity Health to create CommonSpirit Health, Lloyd Dean and Kevin Lofton-–jointly appointed to the role of CEO—must make several operational and strategic decisions related to the integration... View Details
Keywords: Health Care Delivery; Hospital; Merger; Merger Integration; Hospital Mergers; Health Information Technology; CEOs; Health Care and Treatment; Mergers and Acquisitions; Integration; Leadership; Customer Value and Value Chain; Decision Choices and Conditions; Governance; Information Technology; Health Industry; United States
- November 2020 (Revised April 2021)
- Case
Roll-Ups and Surprise Billing: Collisions at the Intersection of Private Equity and Patient Care
By: Trevor Fetter and Kira Seiger
This case describes the increasing investment by private equity (PE) firms in patient care and other healthcare services. The case focuses on investments in physician staffing firms and roll-up strategy investments in physician practice management (PPM). Included in... View Details
Keywords: Business Ventures; Acquisition; Mergers and Acquisitions; Business Model; Change; Disruption; Fluctuation; Trends; Customers; Customer Value and Value Chain; Ethics; Fairness; Finance; Equity; Insurance; Private Equity; Geography; Geographic Scope; Health; Health Care and Treatment; Markets; Demand and Consumers; Supply and Industry; Industry Structures; Ownership; Ownership Type; Private Ownership; Relationships; Agency Theory; Business and Community Relations; Business and Shareholder Relations; Business and Stakeholder Relations; Networks; Strategy; Competition; Consolidation; Expansion; Integration; Horizontal Integration; Vertical Integration; Value; Value Creation; Health Industry; Insurance Industry; United States
- November 12, 2020
- Article
What We Can Learn About Unity from Hostile Takeovers
In the wake of the recent election, the United States faces a fraught, difficult transfer of power. What we know about hostile takeovers in business can provide help in finding a path forward. Leaders on the winning side of the more successful acquisitions emphasized... View Details
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
- November 2020
- Supplement
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
- November 2020
- Case
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
- November 2020 (Revised July 2022)
- Case
Dell Technologies: Bringing the Cloud to the Ground
By: Navid Mojir and V. Kasturi Rangan
The case tells the story of Dell Technologies and its efforts to revitalize its value proposition and escape a commodity trap by acquiring EMC for $67 billion—the largest tech acquisition in history. It also shows the deeply intertwined connections between a company’s... View Details
- October 2020 (Revised July 2023)
- Case
The Walt Disney Company: The 21st Century Fox Acquisition and Digital Distribution
By: David J. Collis
This case describes the acquisition of 21st Century Fox by the Walt Disney Company and the subsequent launch by Disney of three streaming channels to compete with Netflix. View Details
- September 2020 (Revised June 2021)
- Supplement
Eaton Corporation: Portfolio Transformation and The Cost of Capital
By: Benjamin C. Esty, Scott Mayfield and Daniel Fisher
In 2000, Eaton Corporation was a broadly diversified industrial conglomerate. But its strategy was evolving and its focus was narrowing around “power management” and more recently on “intelligent power,” the use of digitally enabled products and services designed to... View Details
- September 2020 (Revised December 2020)
- Supplement
Hitachi Rail Limited (B)
By: David J. Collis, Akiko Kanno and Nobuo Sato
This supplement describes the strategy and organisation changes made by British executive, Alistair Dormer, after he is made head of Hitachi Rail's global business. The company acquires an Italian company, continues to win contracts in the UK, but struggles to bring... View Details
- September 2020 (Revised June 2021)
- Case
Eaton Corporation: Portfolio Transformation and The Cost of Capital
By: Benjamin C. Esty, E. Scott Mayfield and Daniel Fisher
In 2000, Eaton Corporation was a broadly diversified industrial conglomerate. But its strategy was evolving and its focus was narrowing around “power management” and more recently on “intelligent power,” the use of digitally enabled products and services designed to... View Details
- June 2020
- Teaching Note
Shiseido Acquires Drunk Elephant
By: Jill Avery
On October 7, 2019, the Shiseido Group announced that it would acquire clean skincare brand Drunk Elephant for $845 million, a valuation of 8.5 times sales. Did Shiseido pay too much or too little for this brand asset? How much was the Drunk Elephant brand worth and... View Details
Keywords: Brand Management; Brand Valuation; Brand Equity; Brand Value; Mergers ＆ Acquisitions; Startup; DTC; Brand Portfolio Strategy; Marketing; Marketing Strategy; Brands and Branding; Mergers and Acquisitions; Valuation; Entrepreneurship; Business Startups; Beauty and Cosmetics Industry; Consumer Products Industry; United States; Japan; Asia; North America
- June 2020
- Supplement
TransDigm: The Acquisition of Aerosonic Corp.
By: Benjamin C. Esty and Daniel W. Fisher
This courseware accompanies the case "TransDigm: The Acquisition of Aerosonic Corp." View Details